CJC-1295 NO DAC 10mg

Overview

CJC-1295 No DAC, often called Modified GRF (1-29), is a synthetic peptide based on the first 29 amino acids of growth hormone–releasing hormone (GHRH). This portion is the active fragment responsible for stimulating the pituitary gland to release growth hormone.

How it works:

• It binds to GHRH receptors in the pituitary gland.
• This triggers the natural release of growth hormone in pulses, mimicking the body’s normal rhythm.
• Unlike the DAC version, the “No DAC” form has a shorter half-life (around 30 minutes), making its effects more natural and controllable.

CJC-1295 (No DAC) : Structure

Type: GHRH (1–29) analog
Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Length: 29 amino acids
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3368.7 g/mol

CJC-1295 No DAC: Research

CJC-1295 No DAC & Intestine

Researchers developed several stable analogues of growth hormone-releasing factor (GRF) to explore their therapeutic potential. One potent analogue, GRF-6, caused severe diarrhea in monkeys during prolonged infusion but had no adverse effects in rats. Since GRF shares structural similarities with VIP/PACAP peptides, which are known to cause diarrhea when overproduced, the study examined whether GRF analogues interact with VIP/PACAP receptors.

Key Results:

• Native hGRF(1-29) had weak binding to rat and human VPAC1/VPAC2 receptors, while VIP bound strongly.
• GRF-6 showed weak binding to rat receptors but higher affinity for the human VPAC1 receptor (not VPAC2).
• In guinea pig pancreatic cells, all GRF analogues acted as full agonists, triggering enzyme release.

Conclusion

Unlike natural hGRF, GRF-6 selectively interacts with the human VPAC1 receptor, which likely explains the diarrhea observed in monkeys. The study highlights important species differences in receptor responses, stressing the need to test peptide agonists on human or closely related cells before therapeutic use.

Thyroid Hormone Therapy Restores Growth Hormone Response to GRF in Hypothyroidism

People with hypothyroidism often show reduced growth hormone (GH) responses. This study tested how GH reacts to growth hormone–releasing factor (GRF) in 14 patients with primary hypothyroidism, both before and after thyroid hormone (T4) replacement therapy.

When patients received daily T4 treatment, their GH response to GRF significantly improved. Peak GH levels nearly doubled, and the overall GH release (measured by the area under the curve) increased in most patients.

Thyroid hormone replacement helps restore the pituitary gland’s ability to respond to GRF, showing that proper thyroid function is important for normal GH regulation in people with hypothyroidism.

Referenced Citations

Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. doi: 10.1016/s0196-9781(01)00436-3. PMID: 11445245.

Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.

 

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products available on this website are intended solely for in-vitro research purposes (Latin: “in glass”), meaning they are used in experiments conducted outside a living organism. These products are not medicines or drugs, have not been evaluated or approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Any administration to humans or animals, whether by ingestion, injection, or other means, is strictly prohibited by law.

Test

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.

Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.

For further information on proper storage techniques, click the link below:

Peptide Storage